Agenzia Italiana del Farmaco
Direct communication with healthcare professionals on Natpar (parathyroid hormone) - Direct communication with healthcare professionals on Natpar (parathyroid hormone)
Direct communication with healthcare professionals on Natpar (parathyroid hormone)
Natpar (parathyroid hormone) 100 micrograms/dose powder and solvent for solution for injection: expected shortage from June 30th, 2022.
Summary:
- Due to manufacturing challenges, Takeda will be unable to supply the 100 micrograms/dose strength from approximately end of June 2022. The duration is unknown but is expected to last at least 6 months.
- Healthcare professionals are advised not to initiate any new patients on any strength of Natpar until the supply issue is resolved.
- For existing patients on 100 mcg once a day, once the 100 micrograms / dose strength is unavailable, healthcare professionals can prescribe an alternative dosing regimen, as per their independent clinical judgment (see details below).
- It is very important to closely monitor serum calcium levels and observe patients for signs and symptoms of hypocalcemia while carefully adjusting active vitamin D and supplemental calcium doses in all patients affected by Natpar 100 micrograms/dose shortage.
Published on: 29 April 2022
Una legislazione farmaceutica moderna è fondamentale per accompagnare l'#innovazione e garantire ai ...
Vai al post →
Si conclude la campagna #MedSafetyWeek di quest’anno! 🎉
Grazie per aver seguito i nostri canali in...
Vai al post →
Se sei un professionista sanitario, cogli l’occasione per discutere e individuare gli effetti indesi...
Vai al post →
💬 Ti è mai capitato di pensare “è solo un’eruzione cutanea”, “sono soltanto stressato” o “probabilm...
Vai al post →
Esistono diversi tipi di effetti indesiderati dei #farmaci: il modo in cui si manifestano può dipend...
Vai al post →
📍 A Roma la seconda edizione del Policy & Business Forum del Gruppo Editoriale @urania.news, import...
Vai al post →
